Daniel P. Petrylak

Dr. Daniel P. Petrylak is a Professor of Medicine (Medical Oncology) and Urology at Yale School of Medicine, and Chief of Genitourinary Oncology. He leads clinical trials for prostate, bladder, kidney, and testicular cancers, focusing on immunotherapy advancements. His work includes pivotal studies on docetaxel therapy for advanced prostate cancer and SWOG trials for genitourinary cancers. He is co-director of the Cancer Signaling Networks Research Program at Yale Cancer Center, studying cancer stem cells and personalized drug matching.

• Affiliations: Yale School of Medicine, Yale Cancer Center, Smilow Cancer Hospital
• Education: MD from Case Western Reserve University School of Medicine (1985)
• Research Interests: Immunotherapy, genitourinary malignancies, clinical trial development, translational research

His research emphasizes translating basic science into clinical practice, such as advancing docetaxel from phase I to III trials. He has authored over 100 peer-reviewed articles and serves as principal investigator on seven SWOG clinical trials. Recent studies focus on pembrolizumab/docetaxel combinations, sacituzumab govitecan, and enfortumab vedotin in bladder and prostate cancers.